Cationic Polymer Structures for Safe, Efficient mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of nucleic acids as therapeutics remains a challenge, particularly in achieving safe and efficient delivery of mRNA for the treatment of various diseases.
Innovation Solution
Cationic polymers with specific monomer structures are developed for the preparation of dry powder pharmaceutical formulations, enhancing the in vivo delivery of therapeutic nucleic acids such as mRNA, and are used in lipid nanoparticles with PEG-modified lipids for targeted administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymers are used for nucleic acid delivery, then delivery capability is achieved, but safety and efficiency are insufficient
Solution Approach 1:
The patent modifies polymer parameters by introducing specific monomer structures with adjustable R1, L1, B1, x, and y groups to optimize both safety and delivery efficiency. The cationic charge density and molecular weight are controlled through these parameter changes to achieve effective nucleic acid complexation while maintaining biocompatibility
Solution Approach 2:
The invention creates composite polymer structures combining multiple functional groups (cationic amines, hydrophobic alkyl chains, and flexible linkers) to achieve synergistic effects. This composite approach allows simultaneous improvement of delivery efficiency through enhanced cell membrane interaction and safety through controlled degradation
2Ease of manufacture
If polymer structure is simplified, then manufacturing is easier, but delivery performance is reduced
Solution Approach 1:
The patent divides the polymer into distinct functional segments: cationic amino acid residues for nucleic acid binding, hydrophobic alkyl chains for membrane interaction, and flexible linkers for conformational adaptability. This segmentation allows each component to be optimized independently while maintaining overall manufacturability through modular synthesis approaches
3Reliability
If polymer molecular weight is increased, then nucleic acid complexation improves, but formulation stability deteriorates
Solution Approach 1:
The patent optimizes molecular weight as a parameter within a specific range (500-5000 Da) to balance complexation capability and formulation stability. The monomer structure parameters (R1, L1, B1 groups) are adjusted to ensure adequate nucleic acid binding while maintaining polymer solubility and resistance to aggregation in pharmaceutical formulations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cationic polymers provide potent and safer delivery of nucleic acids, enabling effective treatment of diseases by improving mRNA delivery and expression in target tissues.
Implementation Method 1
The invention features polymers that comprise monomers having the following structure... B1 is NR2R3 or a 5- to 10-membered heteroaryl group... providing safe and efficient delivery of therapeutic nucleic acids
Data Source
AI summary
Disclosed are cationic polymers comprising monomers such as those described in Formula (I),Such polymers can be useful for the preparation of therapeutic compositions (e.g., compositions comprising nucleic acids such as mRNA). Additionally, therapeutic compositions comprising these cationic, biodegradable polymers can have improved properties and reduced toxicity.